Specific immunotherapy of experimental myasthenia gravis in vitro and in vivo: The Guided Missile strategy

W. Sun, R. N. Adams, A. Miagkov, Y. Lu, H. S. Juon, Daniel B Drachman

Research output: Contribution to journalArticle

Abstract

Current immunotherapy of myasthenia gravis (MG) is often effective, but entails risks of infection and neoplasia. The "Guided Missile" strategy described here is designed to target and eliminate the individual's unique AChR-specific T cell repertoire, without otherwise interfering with the immune system. We genetically engineered dendritic cells to present AChR epitopes and simultaneously express Fas ligand in an ongoing EAMG model. In both in vitro and in vivo experiments, these engineered cells specifically killed AChR-responsive T cells without otherwise damaging the immune system. AChR antibodies were markedly reduced in the treated mice. Translation of this method to treat human MG is possible.

Original languageEnglish (US)
Pages (from-to)25-32
Number of pages8
JournalJournal of Neuroimmunology
Volume251
Issue number1-2
DOIs
StatePublished - Oct 15 2012

Fingerprint

Autoimmune Experimental Myasthenia Gravis
Myasthenia Gravis
Immunotherapy
Immune System
T-Lymphocytes
Fas Ligand Protein
Dendritic Cells
Epitopes
Antibodies
Infection
Neoplasms
In Vitro Techniques

Keywords

  • Dendritic cells
  • Fas ligand
  • Genetic engineering
  • Guided Missile
  • Myasthenia gravis
  • Specific immunotherapy

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Specific immunotherapy of experimental myasthenia gravis in vitro and in vivo : The Guided Missile strategy. / Sun, W.; Adams, R. N.; Miagkov, A.; Lu, Y.; Juon, H. S.; Drachman, Daniel B.

In: Journal of Neuroimmunology, Vol. 251, No. 1-2, 15.10.2012, p. 25-32.

Research output: Contribution to journalArticle

Sun, W. ; Adams, R. N. ; Miagkov, A. ; Lu, Y. ; Juon, H. S. ; Drachman, Daniel B. / Specific immunotherapy of experimental myasthenia gravis in vitro and in vivo : The Guided Missile strategy. In: Journal of Neuroimmunology. 2012 ; Vol. 251, No. 1-2. pp. 25-32.
@article{56f08b7fbe2b476790beaafb1fba5136,
title = "Specific immunotherapy of experimental myasthenia gravis in vitro and in vivo: The Guided Missile strategy",
abstract = "Current immunotherapy of myasthenia gravis (MG) is often effective, but entails risks of infection and neoplasia. The {"}Guided Missile{"} strategy described here is designed to target and eliminate the individual's unique AChR-specific T cell repertoire, without otherwise interfering with the immune system. We genetically engineered dendritic cells to present AChR epitopes and simultaneously express Fas ligand in an ongoing EAMG model. In both in vitro and in vivo experiments, these engineered cells specifically killed AChR-responsive T cells without otherwise damaging the immune system. AChR antibodies were markedly reduced in the treated mice. Translation of this method to treat human MG is possible.",
keywords = "Dendritic cells, Fas ligand, Genetic engineering, Guided Missile, Myasthenia gravis, Specific immunotherapy",
author = "W. Sun and Adams, {R. N.} and A. Miagkov and Y. Lu and Juon, {H. S.} and Drachman, {Daniel B}",
year = "2012",
month = "10",
day = "15",
doi = "10.1016/j.jneuroim.2012.06.007",
language = "English (US)",
volume = "251",
pages = "25--32",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Specific immunotherapy of experimental myasthenia gravis in vitro and in vivo

T2 - The Guided Missile strategy

AU - Sun, W.

AU - Adams, R. N.

AU - Miagkov, A.

AU - Lu, Y.

AU - Juon, H. S.

AU - Drachman, Daniel B

PY - 2012/10/15

Y1 - 2012/10/15

N2 - Current immunotherapy of myasthenia gravis (MG) is often effective, but entails risks of infection and neoplasia. The "Guided Missile" strategy described here is designed to target and eliminate the individual's unique AChR-specific T cell repertoire, without otherwise interfering with the immune system. We genetically engineered dendritic cells to present AChR epitopes and simultaneously express Fas ligand in an ongoing EAMG model. In both in vitro and in vivo experiments, these engineered cells specifically killed AChR-responsive T cells without otherwise damaging the immune system. AChR antibodies were markedly reduced in the treated mice. Translation of this method to treat human MG is possible.

AB - Current immunotherapy of myasthenia gravis (MG) is often effective, but entails risks of infection and neoplasia. The "Guided Missile" strategy described here is designed to target and eliminate the individual's unique AChR-specific T cell repertoire, without otherwise interfering with the immune system. We genetically engineered dendritic cells to present AChR epitopes and simultaneously express Fas ligand in an ongoing EAMG model. In both in vitro and in vivo experiments, these engineered cells specifically killed AChR-responsive T cells without otherwise damaging the immune system. AChR antibodies were markedly reduced in the treated mice. Translation of this method to treat human MG is possible.

KW - Dendritic cells

KW - Fas ligand

KW - Genetic engineering

KW - Guided Missile

KW - Myasthenia gravis

KW - Specific immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84865632815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865632815&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2012.06.007

DO - 10.1016/j.jneuroim.2012.06.007

M3 - Article

C2 - 22769060

AN - SCOPUS:84865632815

VL - 251

SP - 25

EP - 32

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -